# Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

> **NCT02001896** · PHASE3 · UNKNOWN · sponsor: **Xinjiang Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** gemcitabine; cisplatin or carboplatin; erlotinib
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT02001896
- **Lead sponsor:** Xinjiang Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001896, "Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02001896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*